COMMUNIQUÉS West-GlobeNewswire

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
09/08/2024
Surpassed 50% Enrollment Milestone in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with NDA Submission on [...]
MedBright AI Announces the Appointment of Christopher Heath as CEO and Termination of Letter of Intent
09/08/2024
VANCOUVER, British Columbia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the " Company " or " MedBright AI ") (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) is pleased to announce that Christopher Heath has [...]
Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on August 15
09/08/2024
MELBOURNE, Australia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/08/2024
BEDFORD, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and [...]
Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
09/08/2024
REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be [...]
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
09/08/2024
$426.4M cash, cash equivalents and marketable securities as of June 30, 2024; Projected cash runway into mid-2026 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical- [...]
Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
09/08/2024
-- Initiated Phase 3 SYNCHRONY Outcomes Trial of Lead Candidate Efruxifermin (EFX) in Patients with Compensated Cirrhosis (F4) Due to MASH -- Presented Poster and Late-breaking Oral Presentation on EFX at the EASL [...]
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference
09/08/2024
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic [...]
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
09/08/2024
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $186 million MHRA and Health Canada approved CARVYKTI ® in earlier lines of treatment for adult patients with relapsed and lenalidomide- [...]
Sharecare announces second quarter 2024 financial results and operational highlights
09/08/2024
ATLANTA, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, today announced financial results for the quarter ended June 30, [...]
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
09/08/2024
Reported interim REGEN-007 data that demonstrate rilparencel’s potential to preserve kidney function in patients with diabetes and advanced CKD Restarted manufacturing and resumed PROACT 1 and PROACT 2 Phase 3 trials [...]
Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results
08/08/2024
CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the second quarter and year-to-date of 2024. Recent Highlights: Second quarter [...]
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
08/08/2024
Unveiled new positive survival data for amezalpat (TPST-1120) in randomized first-line hepatocellular carcinoma (“HCC”) study demonstrating: Survival benefit maintained across key subpopulations a six-month improvement [...]
BRIGHT GREEN ANNOUNCES IT HAS OBTAINED A $3.5 MILLION FUNDING COMMITMENT UNDER AN EXISTING LINE OF CREDIT AND HAS ENGAGED AN INVESTMENT BANK TO SEEK A $15.0 MILLION DEBT FINANCING TO MOVE FORWARD WITH COMMERCIALIZATION.
08/08/2024
GRANTS, NEW MEXICO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that the Company has engaged an investment bank with vast experience to [...]
StateHouse Confirms Resumption of Trading
08/08/2024
SAN DIEGO and TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- StateHouse Holdings Inc . (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF), a California-focused, vertically integrated cannabis company, is pleased to [...]
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
08/08/2024
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate [...]
Vincerx Pharma Reports Second Quarter 2024 Financial Results
08/08/2024
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected at the end of Q3 [...]
SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08/08/2024
Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS which we [...]
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
08/08/2024
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024 ASCO 2024 [...]

Pages